Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity
This Study is
No Longer Enrolling
Child to Adult
Male and Female patients, 12 years of age and above Confirmed diagnosis of a rare genetic obesity caused by a mutation that impacts the function of the MC4 pathway
II - Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Treatment
University of Colorado Hospital
Protocol Number: 17-0373
More information available at ClinicalTrials.gov: NCT03013543
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers